REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine ...
REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds ...
Machine learning-based survival prediction in spinocerebellar ataxia type 3 (SCA3) using DeepSurv, random survival forest, deep Cox mixtures, and Cox proportional hazards models.
In a press release from February 24th, 2026, Vico Therapeutics have announced that participants are now being dosed in a new fourth arm of their ongoing Phase 1/2a clinical trial of VO659, a drug ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company developing genetic medicines for ultra-rare and rare conditions, today announced that the ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the ...
Vico Therapeutics recently presented at several conferences to share an interim update on their Phase 1/2a clinical trial testing their drug called VO659, which targets the repeating C-A-Gs in people ...
Biohaven is on the cusp of a new drug application filing in a rare neurodegenerative disorder that currently has no approved therapies, a surprising development for a molecule with a long list of ...
Despite the agency's refusal to review the application, Biohaven "is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible." (iStock / Getty Images ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results